Galactosylated solid lipid nanoparticles with cucurbitacin B improves the liver targetability

Wang, Wenyu; Zhao, Xin; Hu, Haiyang; Chen, Fan; Gu, Jianchun; Deng, Yihui; Sun, Jin

doi:10.3109/10717540903580176

Cited by 40 publications

(18 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The modified method of Wang et al (2010) was used for the preparation of N-SALB. Briefly, 358.3 mg of LB (1 mmol) and 269.5 mg of SA (1 mmol) were added to 10 mL of methanol, refluxed for 24 hours at 70°C, and the precipitate was collected by filtration with a 0.45-μm Millipore filter (Millipore, Billerica, Massachusetts, USA).…”

Section: Preparation Of Galactosylated Sa and N-salbmentioning

confidence: 99%

Galactosylated nanostructured lipid carriers for delivery of 5-FU to hepatocellular carcinoma

Varshosaz

Hassanzadeh

Sadeghi

et al. 2012

Journal of Liposome Research

View full text Add to dashboard Cite

The aim of the present study was to design a targeted delivery system of 5-fluorouracil (5-FU) for hepatocellular carcinoma (HCC). Lactobionic acid (LB) was conjugated to stearyl amine (SA) by a chemical reaction. The nanostructured lipid carriers (NLCs), containing LB conjugate, lecithin, glyceryl monostearate, oil [oleic acid (OA) or Labrafac 5 or 10%], and 5-FU, were dissolved in alcohol/acetone, the oil phase was added to the aqueous phase containing Tween 80 or Solutol(®) HS15 (0.25 or 0.5%), and NLCs were prepared by an emulsification-solvent diffusion method. Physical properties and drug release were studied in NLCs. The thiazolyl blue tetrazolium bromide assay was used to study the cytotoxicity of NLCs on HepG(2) cells, and the cellular uptake of NLCs was determined by flow cytometry. Fourier transform infrared spectroscopy and (1)H-NMR spectra confirmed the successful conjugation of LB and SA. The optimized NLCs consisted of 0.5% Solutol HS15 and 10% OA oil. The particle size of these nanoparticles was 139.2 nm, with a zeta potential of -18 mV, loading efficiency of 34.2%, release efficiency after 2 hours of the release test was 72.6%, and crystallinity was 0.63%. The galactosylated NLCs of 5-FU were cytotoxic on the HepG(2) cell line in a half concentration of 5-FU and seems promising in reducing 5-FU dose in HCC.

show abstract

Section: Preparation Of Galactosylated Sa and N-salbmentioning

confidence: 99%

Galactosylated nanostructured lipid carriers for delivery of 5-FU to hepatocellular carcinoma

Varshosaz

Hassanzadeh

Sadeghi

et al. 2012

Journal of Liposome Research

View full text Add to dashboard Cite

show abstract

“…Upon binding to the receptor, these proteins are internalized and routed towards the lysosomes for degradation [14]. A wide range of galactose-bearing entities have been described to date, such as solid lipid NPs [15], stimuli-responsive polymers [16] or dendrimers [17] for drug delivery, biodegradable poly(2-(2-aminoethyoxy)ethoxy)phosphazene particles for DNA delivery [18], magnetite NPs [19] as magnetic resonance imaging (MRI) contrast agents or multimodal particles such as magnetite NP-loaded and 99m Tc-labeled chitosan-linoleic acid NPs for MRI, nuclear imaging and gene delivery [20].…”

Section: Introductionmentioning

confidence: 99%

The labeling of cationic iron oxide nanoparticle-resistant hepatocellular carcinoma cells using targeted magnetoliposomes

et al. 2011

View full text Add to dashboard Cite

“…It has been reported that absorption of artemisinin could be modified by other constituents of Artemesia annua as a clinical pharmacokinetic study showed artemisinin formulated as a herbal tea was absorbed rapidly and with shorter Tmax in comparison its administration as capsules [74]. There are several reports on the application of nanotechnology in improving solubility, bioavailability and bioactivity of phytochemicals [75][76][77][78][79]. Besides the use of nanotechnology, this low solubility could be overcome through the use of solid dispersion of water-soluble carriers, prodrugs, self-emulsifying systems, complexation with β-cyclodextrin etc.…”

Section: Poor Aqueous Solubilitymentioning

confidence: 99%

Exploring Nanotechnologies for the Effective Therapy of Malaria Using Plant-Based Medicines

Oga¹,

Singh

2016

CPD

View full text Add to dashboard Cite

Malaria is a potentially lethal disease caused by species of the plasmodium parasite. Despite the advances in the interventions for its control and approaches to manage fatality, morbidity and mortality rates associated with malaria are still high. At present, artemisinin-based combination therapy is the first line of treatment. However, there is the need to explore newer approaches as reduced effectiveness and multi-drug resistance (even to artemisinin) has been reported in some regions and is expected to widen in scope. Phytomedicines have shown promise for the management of this debilitating disease and there are abundant resources in most of the areas where this disease is endemic. This report would systematically review the literature, emphasizing the challenges encountered in the control of malaria, active phytochemicals currently utilised in the management, drug delivery approaches as well as the nanotechnology-based systems that could be exploited in its treatment. These phytomedicines, either delivered conventionally or via the use of advanced delivery systems may suggest new strategies towards the better management of malaria.

show abstract

Galactosylated solid lipid nanoparticles with cucurbitacin B improves the liver targetability

Cited by 40 publications

References 27 publications

Galactosylated nanostructured lipid carriers for delivery of 5-FU to hepatocellular carcinoma

Galactosylated nanostructured lipid carriers for delivery of 5-FU to hepatocellular carcinoma

The labeling of cationic iron oxide nanoparticle-resistant hepatocellular carcinoma cells using targeted magnetoliposomes

Exploring Nanotechnologies for the Effective Therapy of Malaria Using Plant-Based Medicines

Contact Info

Product

Resources

About